Swedbank AB lifted its position in Pfizer Inc. (NYSE:PFE – Free Report) by 12.0% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,150,865 shares of the biopharmaceutical company’s stock after purchasing an additional 660,593 shares during the quarter. Swedbank AB owned 0.11% of Pfizer worth $172,716,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Vermillion Wealth Management Inc. increased its position in shares of Pfizer by 19.4% in the first quarter. Vermillion Wealth Management Inc. now owns 2,352 shares of the biopharmaceutical company’s stock valued at $66,000 after acquiring an additional 382 shares during the period. Triad Wealth Partners LLC raised its stake in Pfizer by 1.9% during the fourth quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company’s stock valued at $510,000 after buying an additional 386 shares during the last quarter. Eagle Capital Management LLC boosted its stake in Pfizer by 0.3% in the 1st quarter. Eagle Capital Management LLC now owns 126,573 shares of the biopharmaceutical company’s stock worth $3,554,000 after purchasing an additional 390 shares in the last quarter. ETF Store Inc. grew its holdings in shares of Pfizer by 3.8% during the fourth quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company’s stock valued at $272,000 after buying an additional 396 shares during the last quarter. Finally, Mattern Wealth Management LLC lifted its holdings in shares of Pfizer by 4.6% during the fourth quarter. Mattern Wealth Management LLC now owns 9,161 shares of the biopharmaceutical company’s stock valued at $228,000 after purchasing an additional 400 shares in the last quarter. 68.36% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
PFE has been the topic of a number of research reports. Wolfe Research restated an “underperform” rating and issued a $26.00 price target on shares of Pfizer in a research note on Thursday, May 14th. Cantor Fitzgerald reissued a “neutral” rating and set a $27.00 price target on shares of Pfizer in a report on Monday. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Saturday. BMO Capital Markets reissued an “outperform” rating on shares of Pfizer in a research note on Tuesday, June 23rd. Finally, Guggenheim lifted their price objective on shares of Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a research note on Tuesday, March 24th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, thirteen have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $28.59.
Pfizer Price Performance
Shares of PFE stock traded up $0.39 during mid-day trading on Tuesday, reaching $24.11. The stock had a trading volume of 15,358,688 shares, compared to its average volume of 42,630,352. Pfizer Inc. has a 12-month low of $23.11 and a 12-month high of $28.75. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. The business has a 50-day simple moving average of $25.63 and a 200 day simple moving average of $26.23. The company has a market cap of $137.43 billion, a P/E ratio of 18.41 and a beta of 0.35.
Pfizer (NYSE:PFE – Get Free Report) last released its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. The company had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The business’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.99 earnings per share for the current year.
Pfizer Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be issued a $0.43 dividend. The ex-dividend date is Friday, July 24th. This represents a $1.72 annualized dividend and a yield of 7.1%. Pfizer’s payout ratio is 131.30%.
Key Headlines Impacting Pfizer
Here are the key news stories impacting Pfizer this week:
- Positive Sentiment: Pfizer won FDA approval for a new IBRANCE use in HR-positive, HER2-positive metastatic breast cancer, adding a fresh clinical and commercial catalyst that could support future sales. Pfizer (PFE) Wins FDA Approval For IBRANCE In HER2 Positive Breast Cancer
- Positive Sentiment: Several articles highlighted Pfizer as a “dirt cheap” healthcare stock, suggesting value investors may see upside if the company can stabilize growth and capitalize on its cash-generating franchise. Pfizer or AstraZeneca: Which Stock Offers Better Long-Term Potential?
- Positive Sentiment: Cantor Fitzgerald reiterated a neutral rating with a $27 price target, implying meaningful upside from recent trading levels and showing Wall Street still sees room for recovery. Benzinga rating note
- Neutral Sentiment: Pfizer Limited announced its annual meeting and proposed a final dividend, but this appears related to a different Pfizer entity and is unlikely to affect Pfizer Inc. shares. Pfizer Limited Sets July 28 Virtual AGM, Proposes Rs 75 Final Dividend
- Neutral Sentiment: Comparisons with AstraZeneca and Alnylam mostly reinforce the view that Pfizer faces stronger near-term growth questions than some peers, but these pieces are more comparative than company-specific. Pfizer or AstraZeneca: Which Stock Offers Better Long-Term Potential?
- Negative Sentiment: Analysts downgraded Pfizer to Hold, citing delayed pipeline catalysts, management changes, and weaker near-term rerating potential, which likely weighed on the stock. Pfizer’s Growth Story Faces a Wait as Pipeline and Leadership Doubts Mount
- Negative Sentiment: Pfizer was also described as sinking while the broader market advanced, reflecting continued investor concern about its growth outlook and keeping pressure on shares. Pfizer (PFE) Stock Sinks As Market Gains: Here’s Why
Pfizer Profile
Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.
Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.
Read More
- Five stocks we like better than Pfizer
- 3 Quiet AI Revenue Accelerators With Sales Growth Outpacing Peers
- Top 135 Best Locally Owned BBQ Supply Stores in the U.S., According to Survey [2026]
- Silicon Starvation: Amazon Feasts on Legacy GPUs
- GE Vernova’s Power Surge Turns the Grid Into an AI Trade
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
